Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 33

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 33
---
 and import a Licensed Product in the Field (the Field means all applications for the treatment of diseases in
humans) or the Product Patent Rights, which claim has not lapsed, been abandoned, been revoked or been held to be unpatentable, invalid
or unenforceable by a final judgment of a court or other governmental agency or competent jurisdiction from which no appeal can be or
is taken within the time allowed for appeal and which has not been admitted to be invalid or unenforceable through reissue, re-examination,
disclaimer or otherwise. Product Patent Rights shall mean any and all our patent rights that are necessary to make, develop, use, sell,
have sold, offer for sale and import a Licensed Product in the Field, including any improvements or patent rights directed to the Licensed
Product. Either party may terminate the Xencor Agreement upon 60 days’ (10 days for any payment default) prior written notice to
the other party after the breach of any material provision of the agreement by the other party if the breaching party has not cured the
breach within the 60-day period (10-day period for any payment default) following written notice of termination by the non-breaching party.
We can terminate the Xencor Agreement upon 180 days prior written notice to Xencor. Xencor may terminate the Xencor Agreement in its entirety
or with respect to any specific Licensed Product upon written notice in the event that we contest, oppose or challenge or assist any party
in contesting, opposing or challenging, Xencor’s ownership of, or the enforceability or validity of the Patent Rights that Xencor
controls as of October 3, 2017 which Patent Rights are necessary to make develop, use, sell, have sold, offered for sale and import a
Licensed Product in the Field. Either party may terminate the Xencor Agreement upon written notice to the other party upon or after the
insolvency, bankruptcy, dissolution or winding up of such other party or the making or seeking to make or arrange an assignment for the
benefit of creditors of such other party or the initiation of proceedings in voluntary or involuntary bankruptcy which proceeding, or
action remains undismissed or unstayed for a period of more than 60 days.

In consideration of the Xencor
Agreement, we agreed to royalty payments and a percentage of any payments received in exchange for a sub-license.

CORDStrom License Agreement – Clinical Trial Data

On February 6